Abstract
The aim of this study was to evaluate the effectiveness of a pharmaceutical grade isoflavone supplement (Inoclim?) 40 mg per capsule of soy extract rich in daidzin and genistin) on the number of hot flashes and night sweats in menopausal African women. This open, prospective, multicenter study involved 140 menopausal women with climacteric symptoms (i.e., a minimum of five hot flashes and/or moderate to severe night sweats per day). These patients received a daily 40-mg supplement of soy isoflavone contained in an Inoclim? capsule (Laboratoire Innotech International, France). The dose was increased to two capsules per day when there were more than five hot flashes or when the women could not sleep because of night sweats. The patients were followed up over a 4-month period and data were analyzed using EPI-InfoTM version 3.5.1. The outcome measure was fewer hot flashes and night sweats. The mean daily number of episodes of hot flashes was 5.7 at baseline and 1.8 at week 16, corresponding to a decrease of 68.4% (n = 93 patients at baseline and n = 66 at 16 weeks). The mean number of daily episodes of night sweats was 3.7 at baseline and 0.8 at week 16, corresponding to a decrease of 78.4% (n = 127 patients in the first week and n = 73 at 16 weeks). Over 80% of patients took a single one 40 mg capsule per day. The percentage of patients who adhered to the prescription was more than 95% during the 4-month follow-up period. These results confirm the effectiveness of a pharmaceutical grade isoflavone supplement (40 mg, rich in genistin and daidzin) on vasomotor symptoms in menopausal women.
Highlights
The most common symptoms associated with menopause include vasomotor instability, decreased libido, vaginal dryness, insomnia, and bone or joint disorders
The aim of this study was to evaluate the effectiveness of a pharmaceutical grade isoflavone supplement (Inoclim®) 40 mg per capsule of soy extract rich in daidzin and genistin) on the number of hot flashes and night sweats in menopausal African women
A progressive decrease in the number of hot flashes and night sweats was observed during the 16 weeks of follow-up (Figure 1)
Summary
The most common symptoms associated with menopause include vasomotor instability, decreased libido, vaginal dryness, insomnia, and bone or joint disorders. Hot flashes and sweating are estimated to affect 80% of the female population in Western countries. This prevalence is lower in Southeast Asian populations [2]. With regard to African women, few studies are available in the relevant literature, and those that exist mainly reflect a lack of information on menopause (e.g., symptoms and available treatments) [3,4,5,6,7]. The prevalence of climacteric disorders varies according to studies from 57% to 85%, and their management remains inadequate [4,5,6]. The age of menopause onset seems to be slightly hi-
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
